Journals / International Journal of Medical Biochemistry / 2021 / Cilt: 4 - Sayı: 3

Development and optimization of a new aptamer-based method for P-selectin (CD62p) measurement

Pages
192–199
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The aptamer method to measure CD62p proved to be a sensitive, specific, time-saving, and low-cost op tion.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Disease-specific biomarkers are an essential tool for the efficient management of pathological conditions, including susceptibility determination, diagnosis, and preventive monitoring.
📊
Key Findings & Data:P-selectin (CD62p) is selectively ex pressed after platelet activation, and is involved in thrombus formation and immune response.
💡
Conclusion & Impact:Conclusion: The aptamer method to measure CD62p proved to be a sensitive, specific, time-saving, and low-cost op tion.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: Disease-specific biomarkers are an essential tool for the efficient management of pathological conditions, including susceptibility determination, diagnosis, and preventive monitoring. P-selectin (CD62p) is selectively ex pressed after platelet activation, and is involved in thrombus formation and immune response. The serum and plasma level of CD62p increases in conditions such as heart attack, stroke, some immune diseases, and cancer. The aim of this study was to develop a new, aptamer-based method for CD62p measurement. Methods: Aptamers can be used to target specific biomarkers based on their molecular shape. The systematic evolu tion of ligands by exponential enrichment (SELEX) process is a method to identify aptamers with a high affinity for a specific macromolecular target. This study explored using aptamers to measure CD62p. First, aptamers that specifically bind to CD62p were isolated using the SELEX method. The aptamers that demonstrated the highest binding affinity to the CD62p protein were used to coat 96-well plates. Next, the level of CD62p in human serum was measured using this aptamer and the test performance parameters of sensitivity, specificity, and precision were evaluated. Results: Among the aptamers used, Apt-1, Apt-2, and Apt-3, bound to CD62p protein with high affinity. Apt-2 had the greatest binding affinity to CD62, demonstrating a binding constant of -9.6 kcal/mol, and a dissociation constant (Kd) of 18.15±2.36 nM. Bovine serum albumin was used in the specificity test as a negative control. No binding between the selected aptamers and this protein was observed. The performance showed that of intra-assay coefficient of variation (CV) was <6.52% and inter-assay CV was <3.96%. The recovery values were between 95.06% and 107.95%, and the lin earity values were between 99.49% and 113.17%. Sensitivity was calculated at 0.30 ng/mL of CD62p. Conclusion: The aptamer method to measure CD62p proved to be a sensitive, specific, time-saving, and low-cost op tion.

🔖

Cite This Article

ERDOĞAN, Ö., AL-SAADI, M. S., ÇEVİK, E., ÇEVİK, Ö. (2021). Development and optimization of a new aptamer-based method for P-selectin (CD62p) measurement. International Journal of Medical Biochemistry, Cilt: 4 - Sayı: 3, 192–199. https://ajindex.com/articles/406969

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Cummings RD, Smith DF. The selectin family of carbohydrate-binding proteins: structure and importance of carbohydrate ligands for cell adhesion. Bioessays 1992;14(12):849–56
  2. Ushiyama S, Laue TM, Moore KL, Erickson HP, McEver RP. Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin. J Biol Chem 1993;268(20):15229–37
  3. Berger G, Hartwell DW, Wagner DD. P-Selectin and platelet clearance. Blood 1998;92(11):4446–52
  4. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003;101(7):2661–6
  5. Lorant DE, Topham MK, Whatley RE, McEver RP, McIntyre TM, Prescott SM, et al. Inflammatory roles of P-selectin. J Clin Invest 1993;92(2):559–70
  6. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002;14(5):581–6
  7. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins--potential pharmacological targets? Drug Discov Today 2006;11(21-22):1034–40
  8. Kappelmayer J, Nagy B Jr, Miszti-Blasius K, Hevessy Z, Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004;42(5):475–86
  9. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24(24):2166–79. Erratum in: Eur Heart J 2006;27(4):501
  10. Missailidis S, Hardy A. Aptamers as inhibitors of target proteins. Expert Opin Ther Pat 2009;19(8):1073–82
  11. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids 2014;3(8):e182
  12. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70(1):307–15
  13. Whiss PA, Andersson RG, Srinivas U. Modulation of P-selectin expression on isolated human platelets by an NO donor assessed by a novel ELISA application. J Immunol Methods 1997;200(1-2):135–43
  14. Gestwicki JE, Cairo CW, Mann DA, Owen RM, Kiessling LL. Selective immobilization of multivalent ligands for surface plasmon resonance and fluorescence microscopy. Anal Biochem 2002;305(2):149–55
  15. Murray KS, Rouse JC, Tangarone BS, Peterson KA, Van Cleave VH. Identification of human serum interferants in the recombinant P-selectin glycoprotein ligand-1 clinical ELISA using MALDI MS and RP-HPLC. J Immunol Methods 2001;255(1- 2):41–56
  16. Kordasht HK, Hasanzadeh M. Aptamer based recognition of cancer cells: recent pr